Review

Neuroprotective Effects of Celastrol in Neurodegenerative Diseases-Unscramble Its Major Mechanisms of Action and Targets

Dandan Liu¹, 2,#, Qian Zhang¹, 2,#, Piao Luo¹, 2,#, Liwei Gu¹, Shengnan Shen¹, Huan Tang¹, Ying Zhang¹, Ming Lyu¹, Qiaoli Shi¹, Chuanbin Yang³*, Jigang Wang¹, 2, 3, 4*

¹Artemisinin research center, and Institute of Chinese Materia Medica, China Academy of Chinese Medical Sciences, Beijing, China. ²Central People's Hospital of Zhanjiang, Zhanjiang, Guangdong, China. ³Department of Geriatrics, Shenzhen People's Hospital, Shenzhen, China. ⁴Department of Pharmacology, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore.

[Received October 4, 2021; Revised November 14, 2021; Accepted November 15, 2021]

ABSTRACT: There are rarely new therapeutic breakthroughs present for neurodegenerative diseases in the last decades. Thus, new effective drugs are urgently needed for millions of patients with neurodegenerative diseases. Celastrol, a pentacyclic triterpenoid compound, is one of the main active ingredients isolated from Tripterygium wilfordii Hook. f. that has multiple biological activities. Recently, amount evidence indicates that celastrol exerts neuroprotective effects and holds therapeutic potential to serve as a novel agent for neurodegenerative diseases. This review focuses on the therapeutic efficacy and major regulatory mechanisms of celastrol to rescue damaged neurons, restore normal cognitive and sensory motor functions in neurodegenerative diseases. Importantly, we highlight recent progress regarding identification of the drug targets of celastrol by using advanced quantitative chemical proteomics technology. Overall, this review provides novel insights into the pharmacological activities and therapeutic potential of celastrol for incurable neurodegenerative diseases.

Key words: celastrol, neurodegenerative diseases, neuroprotective, quantitative chemical proteomics, target

Medicinal plant Tripterygium wilfordii Hook. f. (thunder god vine) based prescriptions have been widely used for inflammatory or autoimmune diseases in China clinical practice, including rheumatoid arthritis, nephritis, lupus erythematosus, thrombocytopenic purpura, etc [1]. Celastrol, one of the main bioactive substances present in Tripterygium wilfordii Hook. f., has a wide range of biological activities. Celastrol has been investigated as a potential therapeutic agent for various diseases, including cancer [2], neurodegenerative diseases [3] and obesity [4]. Neurodegenerative diseases are the most serious health problems in older adults worldwide, with the common characteristics of cognitive impairment, progressive degeneration, loss of neurons and myelin sheath in the central nervous system (CNS). With the aging community increasing, the number of patients with neurodegenerative disease will increase greatly and hunting for effective treatments or drugs with low side effects and clear efficacy is a matter of great urgency [5]. The potential superiorities of celastrol in CNS diseases have gradually become prominent. Many preclinical studies have confirmed that celastrol opens the possibility of therapy...
against multiple neurodegenerative diseases, including chronic neurodegenerative diseases such as Alzheimer’s disease (AD), Parkinson’s disease (PD), Huntington’s disease (HD) and amyotrophic lateral sclerosis (ALS), and acute neurodegenerative diseases including stroke and traumatic brain injury (TBI) [3]. Here, we will comprehensively and critically introduce the major neuroprotective effects, mechanisms, and targets of celastrol in chronic and acute neurodegenerative diseases, and the potential side effects of celastrol will also be included. The detailed experimental studies of celastrol on CNS cells and neurodegenerative diseases in recent years are summarized in Table 1 and Figure 1.

Table 1. The detailed experimental studies of celastrol on CNS cells and neurodegenerative diseases.

| Effects of celastrol on CNS cells and diseases | In vitro or in vivo | Models | Mechanisms of action of celastrol | Refs. |
|-----------------------------------------------|--------------------|--------|----------------------------------|-------|
| Microglia activation                          |                    |        |                                  |       |
| Microglia cell line MG6                       |                    | dsRNA [poly(I:C)]-induced activation | preventing F-actin rearrangement, preventing cytoskeletal alteration, attenuating the expression of proinflammatory cytokines and chemokines | 10    |
| BV-2 microglia cells                          |                    | LPS-stimulated activation             | inhibiting LPS-induced phosphorylation of MAPK/ERK1/2 and NF-κB activation | 11    |
| Female SD rats                                |                    | SCI model                               | inhibiting the activation of microglia and microglia pyroptosis, down-regulating the release of pro-inflammatory cytokines and up-regulating the expression of anti-inflammatory cytokine and reducing the expression of NLRP3 inflammasome by inhibiting the expression of NF-κB/p-p65 | 12    |
| BV-2 microglia cells                          |                    | LPS/ATP induced microglrosis           |                                  |       |
| Inflammatory responses of astrocytes          |                    | CRT-MG human astroglial cells          | HIV-1 Tat (trans-activator of transcription)-induced inflammatory responses | 16    |
|                                               |                    | Poly (I:C) activated neuro-inflammation | suppressing ICAM-1/VCAM-1, chemokines expression and activation of JNK-STAT1 and NF-κB signaling pathways | 17    |
| Neuronal apoptosis and neuro-inflammation     |                    | PC12, SH-SY5Y cells and primary neurons | Cells were treated with Cd (10 μM and/or 20 μM) for 24 h (1) inactivating JNK and Akt/mTOR signaling pathway and elevating PTEN activity; (2) inhibiting CaMKII-dependent Akt/mTOR pathway; (3) suppressing mitochondrial ROS-dependent AMPK-mTOR signaling pathway; (4) targeting NOX2-derived ROS-dependent PP5-JNK signaling pathway. | 22-25 |
| BBB dysfunction                               |                    | Murine brain endothelial bEnd3 cells   | OGD model                          | 30    |
| AD                                            | Male SD rats       | i.p. injection of STZ, and inhale 3% sevofoxygen for 2 h | All these dementias like pathology were reversed after celastrol treatment. | 37    |
|                                               | Male SD rats       | Aβ(1-42)-induced rat model of AD      | Celastrol attenuated hippocampal inflammation, improved synaptic function, and maintained hippocampal energy metabolism. | 38    |
|                                               | CHO cell line      | A CHO cell line overexpressing Aβ     | Celastrol inhibited Aβ1-42 and Aβ1-42 production by reducing the β-cleavage of APP, and reduced BACE-1 expression by preventing NF-κB activation | 18    |
|                                               | Transgenic mouse model of AD | A transgenic mouse model of AD overexpressing the human APP695sw mutation and the presenilin-1 mutation M146L (Tg PS1/APPsw) | Celastrol reduced the levels of Aβ, decreased the microgliosis in the cortex, and reduced the levels of both soluble and insoluble Aβ1-38, Aβ1-40 and Aβ1-42. |       |
| SH-SY5Y cells                                 |                    | Tau hyperphosphorylation induced by Aβ1-42 | Aβ1-42 induced Tau hyperphosphorylation and HSP90 expression were inhibited by celastrol | 39    |
| SH-SY5Y cells, C57BL/6J and APP23 mice primary hippocampal neurons |                    | None | In addition to increased expression of HSP40, HSP70 and HSP90, celastrol induced activation of HSF1 and promoted the TTR transcription in SH-SY5Y cells. | 40    |
| C57BL/6J, transgenic mouse model of AD         |                    | APP23 AD model mice, APP23/Tt+/-(APP23 mice on Tlr knock-out background) mouse strains |                                  |       |
| H4 human neuroglioma cells stably transfected to overexpress human full length APP |                    | LPS induced neuroinflammation | Celastrol increased HSP-70 and Bcl-2 expression, decreased NF-κB, COX-2, phosphorylated GSK-3β expression and ROS production. | 43    |
# Neuroprotective Effects of Celastrol in Neurodegenerative Diseases

| PD                                                                 | A Drosophila DJ-1A RNAi model of PD | Celastrol prevented the loss of DN and restored dopamine content to near normal levels. | 45 |
|------------------------------------------------------------------|-------------------------------------|----------------------------------------------------------------------------------|----|
| Swiss Webster mice and genetically modified mice (Nrf2-KO, NLRP3-KO and Caspase-1-KO) | Rotenone-induced PD model | Celastrol attenuated the loss of dopaminergic neuron in the SNpc and reduced depletion of striatal dopamine levels, increased HSP70 expression to attenuate inflammation by preventing TNF-α and NF-κB activation. | 19 |
| Male C57BL/6 mice and genetically modified mice (Nrf2-KO, NLRP3-KO and Caspase-1-KO) | MPTP-induced PD mouse model and AAV-mediated human α-synuclein overexpression PD model | Celastrol relieved motor deficits and nigrostriatal dopaminergic degeneration through Nrf2-NLRP3-caspase-1 pathway. | 46 |
| SH-SY5Y cells                                                   | Rotenone-induced PD model | Celastrol suppressed oxidative stress, provided antiapoptotic effects to maintain the mitochondrial function and induced autophagy to clear damaged mitochondria. | 47 |
| SH-SY5Y cells                                                   | SH-SY5Y cells were treated with 1 mM MPP⁺ for 24 h to induced about 50% neuronal death. | Celastrol treatment suppressed MPP⁺-induced injuries by activating autophagy through MAPK/p38, MAPK/ERK, MAPK/Akt, or MAPK/JNK signaling pathways. | 26 |
| Male C57BL/6 mice                                               | Mice received i.p. injections of MPTP (10 mg/kg/day for 3 days) 24 h after the last celastrol injection | Celastrol increased Bcl-2 expression in the substantia nigra by enhancing mitophagy to clear impaired mitochondria and further inhibiting dopaminergic neuronal apoptosis | 51 |
| MS                                                              | EAE animal model | Celastrol suppressed pathogenic Th17 polarization in the peripheral lymph nodes, downregulated cytokine production in BMDCs and inhibited T cells infiltration into the CNS and Th17 cell responses in the CNS. | 52 |
| Male SD rats                                                    | EAE animal model | Celastrol attenuated demyelination and inflammatory infiltration in spinal cord. Celastrol also attenuated optic neuritis by inhibiting cytokines and microgliosis production, expression of iNOS and activation of NF-κB in optic nerve, and attenuating ganglion cells apoptosis in the retina of EAE rats. | 53 |
| Male C57BL/6 mice                                               | EAE animal model | Celastrol modulated MAPK (p38, ERK) to regulate the downstream genes encoding SGK1, so as to restore the Th17/Treg balance and enhance BDNF expression in T cells, and lead to protection against EAE. | 54 |
| Female SD rats                                                  | EAE animal model | Celastrol transformed cytokines profile from Th1 to Th2 pattern, with decreasing TNF-α and increasing IL-10 correspondingly. Celastrol also decreased NF-κB expression, nitrites levels, and immune-histochemical expression of TLR2 and CD3+ T-lymphocytic count. | 55 |
| ALS                                                             | G93A transgenic familial ALS mice (high expresser line) | Celastrol inhibited proinflammatory cytokine and glial activation through reducing TNF-α, iNOS, CD40, GFAP and increasing HSP70 immunoreactivity in lumbar spinal cord neurons. | 56 |
| Primary motoneuron cultures                                    | Cellular stress, such as staurosporin and H₂O₂, to induce apoptosis and oxidative stress | Celastrol did not appear any neuroprotective effect and exhibited neurotoxic. | 57, 58 |
| Polymethylfumalatine expansions (diseases)                      | Male Lewis rats | Succinate dehydrogenase inhibitor 3-NP-induced HD | Celastrol reduced neurotoxicity by decreasing the striatal lesion volumes, inducing HSP70 in the striata, and reducing astrogliosis. | 19 |
| HeLa cells, PC12 cells, HSF1⁺ and HSF1− mouse embryo fibroblast (MEF) cells | Polyglutamine aggregation and toxicity is transfection of a Q57-YFP fusion protein into cell lines | Celastrol effectively decreased the aggregation and toxicity of polyglutamine expression in vitro via stimulating HSF1 activity to lead to inducible HSP70 gene expression pathway. | 60, 61 |
| SCA14                                                           | SH-SY5Y, CHO, and COS-7 cells, primary cultured Purkinje cells | Adenovirus infection | Celastrol induced upregulation of HSP70 and HSP40 to synergistic diminish aggregation formation of mutant PKCy and cells death. Celastrol activated autophagy also benefited for clearing the PKCy aggregates. | 63 |
| Male C57BL/6N mice                                              | Pharmacological induction of HSPs | Celastrol treatment upregulated HSP70 by penetrating the mouse cerebellum. | 64 |
| Stroke                                                          | Male SD rats | pMCAO model | Celastrol downregulated the expression of p-JNK, p-c-Jun and NF-κB. | 67 |
| AIS patients                                                    | Clinical samples | Celastrol treatment increased IL-33 and IL-10 expression, and decreased IL-1β, IL-6, and TNF-α. | 13 |
| Male SD rats                                                    | pMCAO model | Celastrol treatment increased IL-33 and IL-10 expression, and decreased IL-1β, IL-6, and TNF-α. | 13 |
### Effects of celastrol on CNS cells

**Celastrol inhibits neuro-inflammation in microglia**

Manipulation of the inflammatory responses offers an effective pathway for protecting brain cells from injuries induced by various neurodegenerative diseases. As the key innate immune cells in the CNS, rapidly activated microglial cells remove necrotic neurons in response to miscellaneous stress conditions in the nervous system. However, excessive activated microglial cells cause damages to the neurons, which may contribute to the pathogenesis of neuro-inflammatory disorders, such as neurodegenerative diseases [6] and autoimmune diseases of the CNS [7]. The activated microglia change ramified morphology to de-ramified and play a dual role in the CNS injuries according to the phenotypes activated. Chronic activated M1 phenotype is a detrimental state of microglia by producing neurotoxic substances to exacerbate brain injury, and transient M2 phenotype is a neuroprotective phenotype that followed by a shift to M1. Selective inhibiting M1 or increasing M2 phenotype polarization may be an effective strategy to decrease CNS inflammatory responses [8, 9]. It has been shown that celastrol skew M1 to M2 phenotype in microglia in several disease models. After microglial cell line MG6 activation, celastrol inhibited morphological changes of microglia by preventing F-actin rearrangement, prevented cytoskeletal alteration, attenuated the expression of pro-inflammatory cytokines and chemokines [10]. In lipopolysaccharide (LPS)-activated mouse microglia BV-2 cells, celastrol attenuated pro-inflammatory cytokines and nitric oxide (NO) production via inhibiting LPS-induced phosphorylation of MAPK/ERK1/2 and NF-κB activation [11]. In the rat spinal cord injury (SCI) model, celastrol inhibited the activation of M1 microglia in the spinal cord and microglia pyroptosis. Celastrol also down-regulated the release of pro-inflammatory cytokines, enhanced the expression of anti-inflammatory cytokines and reduced the expression of NLRP3 inflammasome by inhibiting the NF-κB/p-p65 expression [12]. In the rat permanent middle cerebral artery occlusion (MCAO) model, celastrol treatment reduced ischemia stroke-induced brain damage with reducing M1 expression and increasing M2 polarization [13]. These results give us a hint that celastrol inhibits neuro-inflammation in microglia by increasing M2-type to regulate the inflammation factors.

| Primary rats neurons and microglia | OGD model | level in vitro and in vivo. The neuroprotective and anti-inflammatory effects of celastrol for ischemic stroke were derived from promoting growth ST2/IL-33 activation in microglia. |
|-----------------------------------|-----------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Primary microglia-entriched cultures | Microglial polarization: microglia were transfected with a ST2 interference vector before pretreatment with OGD for 3 h, then treated with 50 ng/mL IL-33 | |
| Primary rats neuronal | Neurons underwent OGD for 3 h after which they were treated with different concentrations of IL-33 | |
| Male SD rats | Transient global cerebral ischemia reperfusion | Celastrol inhibited HMGB1/NF-κB signaling pathway. |
| Primary rats neuronal | OGD model | Celastrol directly bound to HMGB1 to inactivate it, up-regulated HSP70 and down-regulated NF-κB expression to play neuroprotective effect in cerebral ischemia reperfusion injury in vitro and in vivo. |
| Male SD rats | MCAO model | |
| Male C57BL/6 mice | MCAO model | Celastrol exhibited neuroprotection and anti-apoptosis effects partially by modulating lipid metabolites. |
| Hippocampal cell line (HT-22) cells | OGD model | Celastrol significantly attenuated I/R-induced hippocampal injury by inhibiting the AK005401/MAP3K12 signaling and activating the PI3K/Akt pathway. |
| Male C57BL/6 mice | Bilateral common carotid clip reperfusion | |
| Male SD rats | SAH endovascular perforation model | Celastrol attenuated brain swelling and protected BBB integrity after rats SAH by decreasing MMP-9 expression and attenuating pro-inflammatory cytokines expression. |
| TBI | hsp110-deficient mice, hsp70.1 and hsp70.3 (named hsp70)-deficient mouse lines with C57BL/6 genetic background | Controlled Cortical Impact (CCI) | By increasing the levels of HSP70/HSP110, celastrol inhibited HMGB1 to inactivate it, reduced cellular apoptosis, inflammatory cells infiltration and gliosis, and increased Ki-67-positive cells and improved behavior. |

**Effects of celastrol on CNS cells**

**Celastrol inhibits neuro-inflammation in microglia**

Manipulation of the inflammatory responses offers an effective pathway for protecting brain cells from injuries induced by various neurodegenerative diseases. As the key innate immune cells in the CNS, rapidly activated microglial cells remove necrotic neurons in response to miscellaneous stress conditions in the nervous system. However, excessive activated microglial cells cause damages to the neurons, which may contribute to the pathogenesis of neuro-inflammatory disorders, such as neurodegenerative diseases [6] and autoimmune diseases of the CNS [7]. The activated microglia change ramified morphology to de-ramified and play a dual role in the CNS injuries according to the phenotypes activated. Chronic activated M1 phenotype is a detrimental state of microglia by producing neurotoxic substances to exacerbate brain injury, and transient M2 phenotype is a neuroprotective phenotype that followed by a shift to M1. Selective inhibiting M1 or increasing M2 phenotype polarization may be an effective strategy to decrease CNS inflammatory responses [8, 9]. It has been shown that celastrol skew M1 to M2 phenotype in microglia in several disease models. After microglial cell line MG6 activation, celastrol inhibited morphological changes of microglia by preventing F-actin rearrangement, prevented cytoskeletal alteration, attenuated the expression of pro-inflammatory cytokines and chemokines [10]. In lipopolysaccharide (LPS)-activated mouse microglia BV-2 cells, celastrol attenuated pro-inflammatory cytokines and nitric oxide (NO) production via inhibiting LPS-induced phosphorylation of MAPK/ERK1/2 and NF-κB activation [11]. In the rat spinal cord injury (SCI) model, celastrol inhibited the activation of M1 microglia in the spinal cord and microglia pyroptosis. Celastrol also down-regulated the release of pro-inflammatory cytokines, enhanced the expression of anti-inflammatory cytokines and reduced the expression of NLRP3 inflammasome by inhibiting the NF-κB/p-p65 expression [12]. In the rat permanent middle cerebral artery occlusion (MCAO) model, celastrol treatment reduced ischemia stroke-induced brain damage with reducing M1 expression and increasing M2 polarization [13]. These results give us a hint that celastrol inhibits neuro-inflammation in microglia by increasing M2-type to regulate the inflammation factors.
Figure 1. The detailed experimental studies of celastrol on CNS cells and neurodegenerative diseases. (A) The specific structure of BBB and the effects of celastrol on CNS cells. Celastrol inhibits neuroinflammation in microglia and astrocytes, prevents neuronal apoptosis and neuroinflammation, and maintains the integrity of BBB. (B) Preclinical studies on neurodegenerative diseases that have been studied with celastrol. Celastrol shows neuroprotective effects for multiple neurodegenerative diseases.

**Celastrol inhibits abnormal activated astrocytes**

Astrocytes have significant effects in the CNS by maintaining neuronal homeostasis, regulating reactive oxygen species (ROS), preserving barrier functions for blood–brain barrier (BBB). Microglia and astrocytes usually become reactive in concert after pathological situations in the brain. Abnormally reactive astrocytes actively participate in the progression of neurodegenerative diseases [14, 15]. In HIV-1 Tat (transactivator of transcription)-and poly (I:C) stimulated CRT-MG human astroglia cells, celastrol exerted anti-inflammatory effect by decreasing intercellular adhesion molecule-1 (ICAM-1) and vascular cell adhesion molecule-1 (VCAM-1) expression and inhibiting production of pro-inflammatory chemokines. These effects were mediated by preventing the signaling pathways of JNK MAPK-AP-1/NF-κB and inducing the expression of HO-1 [16, 17]. In the APP/PS1 AD mouse model, celastrol inhibited astrocytes activation and ameliorated AD pathologies [18]. In addition, celastrol powerfully reduced neurotoxin 3-nitropropionic acid (3-NP)-induced rat astrogliosis (reactive astrocytes) [19]. These results indicate that celastrol inhibits abnormal activation of astrocytes to reduce CNS inflammatory reactions.

**Celastrol prevents neuronal apoptosis and neuroinflammation**

The toxic transition metal Cadmium (Cd) is currently one of the leading occupational and environmental exposure hazard factors mainly due to its water-soluble property. The long biological half-life (20-30 years in human) and low excretion rate of Cd responsible for its accumulation and toxicity in human organs. Cd possesses high BBB permeability, and induces neurotoxicity partly by increasing ROS, inflammation, neuronal apoptosis and finally may induce neurodegenerative diseases [20, 21]. In neurons, celastrol prevented Cd-induced neuronal apoptosis via the following signaling pathways: (1) inactivating JNK and Akt/mTOR signaling pathway and elevating PTEN activity [22]; (2) inhibiting CaMKII-dependent Akt/mTOR pathway [23]; (3) suppressing mitochondrial ROS-dependent AMPK-mTOR signaling pathway [24]; (4) targeting NOX2-derived ROS-dependent PP5-JNK signaling pathway [25]. Overall, celastrol has shown its unique advantages in preventing or reversing Cd-induced oxidative stress and neuronal...
apoptosis in neurodegenerative diseases. Celastrol also exerted neuroprotection in PD model by activating mitophagy to inhibit dopaminergic neurons (DN) apoptosis [26]. In addition, celastrol treatment significantly attenuated the DN loss in the substantia nigra pars compacta (SNpc) by inducing heat shock protein (HSP)70 expression and decreasing activation of inflammatory pathways [19]. In a recent study, we found that celastrol significantly reduced the primary rat cortical neurons damage caused by oxygen glucose deprivation (OGD) injury and decreased neurons pathological changes in male adult rats of MCAO model [27]. In general, celastrol prevents neuronal injury by inhibiting apoptosis and neuro-inflammation and increasing antioxidant stress capacity.

**Celastrol maintains the integrity of BBB**

BBB acts as a goalkeeper by restricting access of bloodborne substances and cells to the CNS. CNS disorders often are accompanied by severe changes in the integrity and function of BBB by disrupting tight junction and changing the permeability. Restoring the tight junction is a promising target to maintain the CNS homeostasis and BBB integrity [28, 29]. In murine brain endothelial bEnd3 cells OGD model, celastrol could effectively maintain the tight junction integrity by ameliorating permeability of endothelial monolayers, attenuating loss of occludin, claudin-5 and zonula occludens-1 (ZO-1) as well as inhibiting macrophage migration [30]. These effects were related to celastrol induced activation of MAPKs and PI3K/Akt/mTOR pathways [30]. Celastrol ameliorated tight junction protein disruption after rat subarachnoid hemorrhage (SAH) to protect BBB integrity by decreasing MMP-9 expression and attenuating pro-inflammatory cytokines expression [31]. Celastrol is a BBB-penetrable compound, which may lay a foundation for maintaining the integrity of BBB and treating CNS disorders [32]. Overall, we have every reason to believe that celastrol could protect the damaged BBB to maintain the CNS homeostasis.

**Neuroprotective effects of celastrol in neurodegenerative diseases in pre-clinical studies**

Neurodegenerative disorders are generally accompanied with slow consequent progressive dysfunction, as marked by dysregulation of neurons and axons in the CNS that affect different regions of the brain. Chronic neurodegenerative diseases mainly include AD, PD, ALS, HD, multiple sclerosis (MS) and spinocerebellar ataxias (SCAs), and acute neurodegenerative diseases mainly include stroke and TBI [33, 34]. A multitude of factors contribute to the pathogenesis of neurodegenerative diseases, including accumulation of unfolded/misfolded proteins, abnormal cellular transport, neuro-inflammation, oxidative stress, mitochondrial dysfunction, excite-toxicity, intracellular Ca²⁺ overload, abnormalities in the Genome, and apoptosis [35, 36].

**Celastrol and AD**

As the most common form of dementia, two main neuropathological hallmarks exhibit in the brains of AD patients: (1) the extracellular neuritic plaques and insoluble Aβ species deposit; and (2) intracellular neurofibrillary tangles containing abnormal hyper-phosphorylated microtubule-associated protein Tau. Current treatments for AD in clinical mainly target symptomatic treatments with cholinesterase inhibitors and glutamate antagonists, and disease-modifying pharmacologic treatments are very limited [5]. Diabetes mellitus (DM) rats after sevoflurane anesthesia showed neuropathological changes similar to AD, including cognition impairment and reduced insulin-like growth factors-1 (IGF-1) expression in the hippocampus. All these dementia-like pathologies were partially reversed after celastrol treatment [37]. Celastrol protected against Aβ25-35 induced rats learning and memory decline by attenuating hippocampal inflammation, improving synaptic function and maintain hippocampal energy metabolism [38]. Celastrol could effectively inhibit Aβ production in the CHO cells and AD mouse models, partly due to decreasing the rate-limited enzyme BACE-1 expression via preventing NF-kB activation [18]. In human neuroblastoma SH-SY5Y cells, Aβ1-42 induced Tau hyperphosphorylation and HSP90 expression were inhibited by celastrol [39]. Several groups showed that celastrol increased the expression of HSP40, HSP70 and HSP90 in SH-SY5Y cells. Celastrol also activated HSF1 to promote the transcription of systemic amyloid precursor transthyretin (TTR) in SH-SY5Y cells [40]. As an evolutionarily conserved protein, TTR serves as an endogenous detoxifier to bind Aβ peptides and regulate their aggregation in a chaperone-like manner in AD transgenic mouse model [41, 42], indicating that the role of celastrol in inhibiting Aβ aggregation may also contribute to its effects in alleviating AD pathology. In H4 human neuroglioma cell overexpressing human full-length APP (H4-APP), celastrol significantly reduced LPS-stimulated Aβ production and accumulation, and cells death. These neuroprotective effects of celastrol were derived from its anti-inflammatory and anti-oxidative stress effects by increasing Bcl-2 and HSP70 expression, decreasing NF-κB, COX-2, GSK-3β expression and ROS production [43]. These results suggest that celastrol has neuroprotective effects in preclinical AD models mainly by inhibiting Aβ.
production and accumulation through anti-inflammatory and anti-oxidative stress effects.

**Celastrol and PD**

PD, the most common movement disorder, is mainly induced by progressive loss of DN in the SNpc, and the depletion of transmitter dopamine in striatum due to aggregation of misfolded α-synuclein, oxidative stress and mitochondria dysfunction [44]. Current pharmacological therapy of PD mainly aims at ameliorating motor symptoms by raising the concentration of functional dopamine in the striatum with dopamine receptor agonism or reducing dopamine metabolism, which could not alleviate or reverse the progression of PD [5]. In a Drosophila DJ-1A RNAi model of PD, with anti-inflammatory and antioxidant properties, celastrol prevented the loss of DN and restored dopamine content close to normal levels [45]. In MPTP-treated mouse model of PD, celastrol reduced neurotoxicity by attenuating the loss of DN in the SNpc and reducing depletion of striatal dopamine levels. Furthermore, celastrol increased HSP70 expression in the SNpc, and induced nuclear translocation of cytoplasmic HSP70 to generate newly expressed HSP70. Induced HSP70 expression attenuated inflammation by preventing TNF-α and NF-κB activation [19]. By using whole-genome deep sequencing analysis and multiple genetically modified mice, the authors verified that celastrol relieved PD deficits by targeting Nrf2-NOxR3-caspase-1 pathway [46]. In neurotoxin rotenone-induced PD model of SH-SY5Y cells, celastrol exhibited neuroprotective effect by suppressing oxidative stress, and showed anti-apoptotic effects to maintain the mitochondrial function and inducing autophagy to clear damaged mitochondria [47]. Autophagy plays a pivotal role in PD by removing damaged mitochondria and taking part in proteolytic degradation of α-synuclein [48]. Therefore, pharmacological enhancement of autophagy may be a viable strategy to combat α-synuclein aggregation and inhibit neuronal death in PD. Gene expression data (GSE8397) showed that autophagic activity in the substantia nigra of the midbrain in sporadic PD patients was lower than that of healthy controls [26]. In SH-SY5Y cells, celastrol treatment suppressed MPP+-induced mitochondrial membrane potential depolarization, ATP reduction and neuronal death by activating autophagy. In the PD mouse model, celastrol treatment significantly improved motor symptoms, decreased MPTP-induced dopaminergic neuronal death and increased Bcl-2 expression. By regulating autophagy and mitophagy-related genes, celastrol modulated the process of autophagosome biogenesis and raised mitophagy by degrading impaired mitochondria and further inhibiting dopaminergic neuronal apoptosis [26]. In general, celastrol exerts neuroprotective effects in PD models derived from multiple pharmacological properties, mainly including increasing HSP70 expression, activating autophagy, anti-inflammatory and antioxidant.

**Celastrol and MS**

MS is a chronic immune-mediated neurodegenerative disease with unknown precise cause and pathogenesis. Inflammation, axonal loss, and demyelination are observed in accompany the very early phase of MS, which are affected by metabolic, oxidative stress, genetic and environment [49, 50]. Celastrol treatment significantly decreased clinical scores by delaying symptoms onset in experimental autoimmune encephalomyelitis (EAE) mice possibly via suppressing pathogenic T helper 17 (Th17) polarization in the peripheral lymph nodes, down-regulating cytokines production in bone-marrow derived dendritic cells (BMDCs), inhibiting T cells infiltration into the CNS and Th17 cells responses in the CNS [51]. Celastrol significantly alleviated neurologic severity of EAE rats by modulating the balance of cytokines to attenuate demyelination and inflammatory infiltration in spinal cord [52]. Acute inflammatory demyelinating optic neuritis may be an initial symptom of MS. Celastrol also attenuated optic neuritis by inhibiting cytokines and microgliosis production, expression of iNOS and activation of NF-κB in optic nerve, and attenuating ganglion cells apoptosis in the retina of EAE rats. Therefore, celastrol exhibited neuroprotective effects through T cells activities regulation, anti-inflammatory and anti-apoptotic effects [52]. In addition, celastrol inhibited the progression of EAE mice via restoring the Th17/Treg balance and enhancing brain-derived neurotrophic factor (BDNF) expression in T cells [53]. Celastrol also significantly transformed cytokines profile from Th1 to Th2 pattern, decreased TNF-α and increased IL-10 and correspondingly decreased NF-κB expression [54]. Based on the above findings, we conclude that celastrol may be a potential drug for MS treating in clinical.

**Celastrol and ALS**

ALS is one of the most common rapidly progressive neurodegenerative disorders affecting the motor neurons and is clinically characterized by dysfunction of the upper and lower motor neurons and global muscle weakness [55]. In the G93A SOD1 transgenic mouse model of ALS, celastrol treatment delayed disease onset and increased survival rate by ameliorating weight loss, improving motor performance and rescuing lumbar spinal cord neurons loss. The neuroprotective effect of celastrol was
related with the inhibition of pro-inflammatory cytokines and glial activation and the increase of HSP70 immuno-reactivity in lumbar spinal cord neurons [56]. The role of celastrol in the treatment of ALS is controversial at present. HSP70 activator arimoclomol protected the primary motoneurons from apoptosis and oxidative stress. While celastrol did not exhibit any neuroprotective effect under the same experimental conditions and exhibited neurotoxic and induced neuronal death even under unstressed condition. Therefore, the authors speculated that the neuroprotective effect of celastrol for the SOD1 mouse was due to its anti-inflammatory and antioxidant effects instead of its anti-apoptotic property [57, 58]. These results suggest that the neuroprotective mechanisms of celastrol in ALS may be debatable and complex, and more in-depth research is necessary in the future.

**Celastrol and HD**

HD is an inherited autosomal dominant neurodegenerative illness of the striatum, which is mainly triggered by excessive expanded polyglutamine segment near the amino terminus of huntingtin to form toxic aggregates [59]. The disorders of HD involve choreiform abnormal movements, cognitive deficits, and psychological changes. Currently, treatment of HD in clinical is only focus on symptoms alleviation [5]. After screening of 1040 FDA approved drugs and small bioactive compounds, celastrol was identified as a polyglutamine aggregation inhibitor [60]. Celastrol effectively decreased the aggregation and toxicity of polyglutamine expression in vitro via stimulating HSF1 activity to lead to HSP70 expression [61]. In neurotoxin 3-NP-induced rats HD model, celastrol reduced neurotoxicity by decreasing the striatal lesion volumes, inducing HSP70 expression in the striata, and reducing astrogliosis [19]. Overall, celastrol may be a therapeutic agent for treating polyglutamine expansion diseases, including HD.

**Celastrol and SCAs**

The autosomal dominantly SCAs are a heterogeneous group of neurodegenerative disorders marked by progressive ataxia and cerebellar atrophy. Effective therapy or drug developments are hampered due to the heterogeneity of the SCAs. Genetically, SCAs include > 40 distinct subtypes based on different genetic loci of the causal gene [62]. More concretely, SCA14 has a frequency of 1-4% of families with SCA and is caused by a missense mutation or deletion of the PRKCG gene to induce neurotoxic amyloid-like fibril protein kinase Cγ (PKCγ) aggregate and affect cerebellar Purkinje cells [62]. In vitro, HSP90 inhibitor celastrol induced up-regulation of HSP70 and HSP40 to synergistic diminish aggregation formation of mutant PKCγ and cells death. Furthermore, celastrol activated autophagy also benefited for clearing the PKCγ aggregates. In vivo, celastrol treatment resulted in up-regulation of HSP70 expression by penetrating the mouse cerebellum. Therefore, HSPs were key endogenous regulators of pathophysiological PKCγ aggregation and HSP90 inhibitor celastrol may be a potential therapeutic medicinal component for treating SCA14 [63]. Celastrol may also play neuroprotective roles in other SCAs subtypes, and relevant research needs to be continued.

**Celastrol and stroke**

Stroke can be divided into ischemia stroke and hemorrhagic stroke (including intracerebral and subarachnoid hemorrhage) and is one of the main causes of long-term disability and death worldwide. Acute ischemia stroke (AIS) is result from thrombosis or embolism occluding a cerebral vessel to induce sudden loss of blood supply to an area of the brain [64]. Recombinant tissue plasminogen activator (rt-PA) is the only pharmacological agent approved by FDA to selectively treat 1-8.5% of hospitalized AIS patients with short time window of 3-4.5 h after the onset of symptoms [65]. Celastrol might have therapy potential for ischemia diseases, for it promoted neovascularization in ischemia tissue by improving the mobilization, migration and tube formation capacities of transplanted endothelial progenitor cells (EPCs) in a mouse hindlimb ischemia model [66]. This result gave a hint that celastrol might increase EPCs therapy effect in stroke. In permanent cerebral ischemia model of rats, celastrol reduced brain water content, neurological deficit and infarct volume by down regulating the expression of p-JNK, NF-κB and p-c-Jun [67]. Celastrol treatment increased anti-inflammatory cytokines (IL-33 and IL-10) expression, and decreased inflammatory cytokines (IL-1β, IL-6, and TNF-α) levels in vitro and in vivo of permanent cerebral ischemia model [13]. The neuroprotective and anti-inflammatory effects of celastrol for ischemia stroke were derived from promoting growth stimulation expressed gene 2 (ST2)/IL-33 activation in microglia [13]. ST2 together with its ligand IL-33 stimulated M2 microglia to produce IL-10, thus improving neurons survival and mitigating cerebral injury after ischemia stroke [68]. In addition, celastrol exhibited anti-inflammatory and antioxidant effects by inhibiting high mobility group box 1 (HMGB1)/NF-κB signaling pathway in rats of transient global cerebral ischemia model [69]. In our recent study, we presented evidence that celastrol directly bound to HMGB1 to inactivate it, up-regulated HSP70 and down-
regulated NF-κB expression to play a neuroprotective effect in cerebral ischemia-reperfusion (I/R) injury in vitro and in vivo [27]. Lipidomics and enrichment analysis after MCAO model in mice showed that celastrol exhibited neuroprotection and anti-apoptosis effects partially by modulating lipid metabolites in sphingolipid and glycerophospholipid metabolism pathways [70]. Celastrol significant attenuated I/R-induced hippocampal injury by inhibiting the AK005401/MAP3K12 signaling and activating the PI3K/Akt pathway [71]. In addition, celastrol attenuated brain swelling and protected the barrier function of BBB in the SAH rats [31]. Overall, celastrol shows obvious neuroprotective roles in a variety of stroke models, and how to promote its clinical transformation is the focus of next research.

**Celastrol and TBI**

TBI caused by external force is among the most common causes of death and long-term disability in young adults with limited therapeutic options. Apart from the acute clinical manifestations, patients with a single severe TBI or repeated mild TBI also contribute to the risk of developing neurodegenerative symptoms in later life, such as psychiatric symptoms, personality change, early dementia and cognitive decline [72]. Considering oxidative stress mediates injury of neuro-inflammation and glutamatergic excite-toxicity, it is speculated that oxidative stress bridge TBI to subsequently increased risk of neurodegeneration via oxidation or carbonylation of key proteins [73]. Compared with wild-type mice, HSP110 or HSP70 deficient mice had increased brain injury and neurons death in response to TBI, which was partly due to the increased production of ROS, subsequently increased expression of pro-apoptotic gene p53 and p53-induced genes (Pigs). Celastrol or BGP-15 (increase the level of HSP70/HSP110) treatment in wild-type mice exhibited lower levels of brain injury, decreased cellular apoptosis, inflammatory cells infiltration and gliosis, and increased Ki-67-positive cells and improved behaviors [74]. These results suggest that it is necessary to research the pathophysiological mechanisms of TBI and neurodegenerative diseases, in order to identify more potential pathways that celastrol influenced in the TBI.

**Key directly binding targets of celastrol in neurodegenerative diseases**

Celastrol interacts with numerous proteins and biological pathways to exert many physiological regulatory roles. Large-scale quantitative proteomics performed in human lymphoblastoid cells demonstrated that various biological pathways were regulated by celastrol, with 158 cellular core proteins were altered at least 1.5 fold in protein levels and 375 proteins as the “mitochondrial core proteins” [75]. Celastrol is a thiol reactivity compound. C2 of A-ring and C6 of B-ring in celastrol are prone to electrophilic reactions, which can undergo a regioselective Michael addition covalent product with the sulphydryl group of cysteine residue [76]. Celastrol exhibited anti-inflammatory activity partly by suppressing TLR4 activation through inhibiting LPS binding to the TLR4/MD2 complex. The inhibitory effects of celastrol were derived from its thiol reactivity that allowed it covalently to bind to the cysteine to form Michael adducts [76]. Soft nucleophiles such as biologically relevant glutathione and cysteine add to the pharmacophore of celastrol in a remarkable stereospecific manner, and the stereo-specificity may explain its protein target selectivity [77]. The multiple biological effects of celastrol were blocked by incubation with excessive free thiols, which indicated a chemical mechanism for biological activity of celastrol via modification of key reactive thiols in proteins [78]. In addition, we have also found that celastrol covalently bound to active cysteine sites of peroxiredoxins (Prdxs) to induce cells apoptosis, thereby exerting anti-fibrotic effect, and the relevant data are being sorted out. Therefore, celastrol is a multi-target compound mainly influenced by its structure. The key directly binding targets of celastrol for neurodegenerative diseases, and the specific path diagrams are summarized in Figure 2.

**Celastrol is a NF-κB inhibitor**

NF-κB is a family of nuclear transcription factors that implicate in diverse biological processes. The aberrant over-activated NF-κB is related with various diseases. NF-κB family has five different polypeptide subunits, including NF-κB1 (p50), NF-κB2 (p52), RelA (p65), RelB and c-Rel. The critical terminal components of the NF-κB signaling are NF-κB, IκB, and IκB kinase (IKK, consists of three subunits: IKKα, IKKβ and IKKγ also termed as NEMO). In a resting state, dimeric NF-κB is sequestered in the cytoplasm in a transcriptionally inactive state by binding to inhibitory IκBs proteins to form stable complexes [79]. Under a variety of cellular stimuli, activated IKK triggers site-specific phosphorylation of IκBα, then rapidly ubiquitinated and degraded by the proteasome complex. IκB degradation is necessary for NF-κB release and activation, and NF-κB translocates to the nucleus following IκBα degradation and activates the transcription of target genes [80]. As a NF-κB inhibitor, celastrol suppresses NF-κB activation and NF-κB target genes expression and has valuable potential for the intervention of NF-κB-dependent pathological conditions. Suppressing the NF-κB activation mainly relates with the following two...
mechanisms: (1) directly targeting cysteine 179 in the activation loop of IKKβ to inhibit IKKα and IKKβ activity; (2) restraining a variety of stimuli-induced degradation of IκBα through inhibiting IκBα phosphorylation [81]. Other proteins related to NF-κB may also be the targets of celastrol. For example, interleukin-1 receptor-associated kinases (IRAKs) have four different IRAK-like molecules: two active kinases (IRAK-1 and IRAK-4) and two inactive kinases (IRAK-2 and IRAK-M). All IRAKs take part in activation of NF-κB and interfering with small compound inhibitors at the level of IRAK-4 is the most immediate approach [82]. In the HepG2 cells treated with palmitic acid (PA) to activate TLR4/NF-κB, celastrol treatment effectively inhibited TLR4-dependent NF-κB activation and activated IRAKs. Knock-down IRAKs with small interfering RNA abolished PA-caused NF-κB activation, so targeting IRAKs was one way in which celastrol inhibited NF-κB activation [83]. As we mentioned earlier, celastrol exhibited neuroprotective effects by inhibiting HMGB1/NF-κB signaling pathway, down-regulated NF-κB expression in stroke and other diseases [27, 69]. These studies remind us that celastrol might be effective for many diseases related with NF-κB activation, and how to make good use of this binding mode to provide ideas for the development of celastrol or other drugs is an important research direction.

![Figure 2. Proposed schematic diagram of celastrol forming covalent Michael adducts through the binding of electrophilic sites with the nucleophilic thiol groups of cysteine residues and directly binding targets.](image)

(A) Celastrol suppresses NF-κB activation by inhibiting IKKα and IKKβ activity and inhibiting IκBα phosphorylation to decrease degradation of IκBα. (B) Celastrol activates HSF1 to up-regulate a wider set of potentially neuroprotective HSPs. Different from the existing N-terminal HSP90 inhibitor, celastrol covalently binds to HSP90 co-chaperone Cdc37 and p23 to disrupt the Cdc37-HSP90 or p23-HSP90 complex. (C) Celastrol directly binds to HMGB1 and inhibits the proinflammatory activity of disulfide isoform HMGB1. (D) Celastrol promotes mitochondrial ubiquitination and autophagy by covalently binding to Nur77 and inducing Nur77 interaction with TRAF2 to inhibit the classical IKK/NF-κB pathway. (E) Celastrol is a direct and selective CB2 agonist and triggers several CB2-mediated downstream signaling pathways to reduce inflammatory responses. (F) Celastrol directly binds and inhibits STAT3 tyrosine phosphorylation and nuclear translocation. (G) Celastrol accelerates the degradation of hnRNP A1 by directly binding with it and modulates hnRNP A1-IκBα-NF-κB-TNF-α pathway.

**Celastrol activates HSF1 and influences HSPs expression**

HSF1 is an evolutionarily conserved transcription factor, which exists predominantly in an inactive form under normal conditions in cytoplasmic. In response to various stimuli, HSF1 translocates into the nucleus to induce the expression of genes encoding HSPs [84]. The impairment of HSF1 activity or its depletion exacerbates protein misfolding and aggregation, and decreases chaperone
HSPs expression, thereby contributing to neurodegenerative diseases progression [84]. Under diverse cytoplasmic proteotoxic stimuli induced neurodegenerative disorders, small-molecule drugs that activate HSF1 could restore protein homeostasis [85]. Orally delivered celastrol promoted cells survival, inhibited inflammation, and maintained cellular homeostasis in apoptosis and inflammation animal disease models relying on HSF1-mediated protein homeostasis [86]. Under lethal stress in HeLa cells and SH-SY5Y cells, celastrol was cytoprotective by activating HSF1 with kinetics similar to heat stress. Celastrol activated HSF1 to induce the expression of chaperone genes (HSP70, HSP40, and HSP27), and lowered the temperature threshold required for the heat shock response [57]. Pharmacological activating HSF1 by celastrol treatment enhanced energy expenditure, mitochondrial function in fat and muscle to protect against obesity and metabolic dysfunction, which was achieved by activation of a peroxisome proliferator-activated receptor γ coactivator-1α (PGC-1α)-dependent metabolic program [87]. PGC1α is related with many pathological conditions associated with mitochondrial dysfunctions and impaired ROS balance, including aging and neurodegenerative disorders. We speculate that elastrol might play a central role in neurodegenerative diseases partly by activating HSF1-PGC1α transcriptional axis, and related research need to be implemented with considering precise control the induction levels of PGC1α for the treatment therapeutic window of PGC1α may be narrow [88].

Heat-inducible members have similar domain structures and functions, and function as molecular chaperones to mediate refolding or degradation of damaged intracellular proteins and enable cells to survive under harsh environments [89]. HSPs play a central role in initiating protein aggregates and removing aggregates to maintain protein homeostasis, so targeting HSPs is a viable strategy to reduce pathogenic protein aggregates for developing neurodegenerative disorder drugs [89]. Celastrol upregulated a wider set of potentially neuroprotective HSPs including HSP27, HSP32 (also known as hemeoxygenase-1, HO-1), HSP70, and HSP70B [90, 91]. Celastrol-induced HSP70 localized to neuronal cells, HSP27 and HSP32 localized to glial cells in cerebral cortical cultures [92]. HSP90 stabilizes the client proteins by inhibiting their ubiquitination. In contrast, HSP70 along with its co-chaperone HSP40 promotes ubiquitination and proteasomal degradation. HSP90 and HSP70 possess opposed effects on client protein stability, so it is effective to put off diseases progression by targeting the protein quality control function of the HSP90/HSP70-based chaperone machinery to inhibit HSP90 or promote HSP70 function [93]. Be different from the existing classical HSP90 inhibitors such as geldanamycin, celastrol covalently bound to Cdc37 (binding site unknown) or formed either an intra- or intermolecular protein disulfide with Cdc37 to inactivate Cdc37 and disrupted the Cdc37-HSP90 complex [94]. Therefore, inducing the HSP90 client protein degradation and increasing HSP70 expression effects of celastrol were achieved by disrupting the protein-protein interaction of HSP90-Cdc37 instead of competing with ATP-binding pocket of HSP90 [95]. For the distinct HSP90 inhibiting mechanism with classic HSP90 inhibitors, celastrol reduced HSP90 interaction with the cochaperone p23 and showed mild synergistic effect with HSP90 inhibitors in anticancer research [96]. Classic inhibitors of HSP90 caused nonsselective degradation of HSP90 client proteins. As the most sensitive target of celastrol, HSP90 co-chaperone p23 was bound by celastrol and co-chaperone structure was altered by altering its three-dimensional structure and triggering its oligomerization into amyloid-like fibrils, so as to more selective destabilization of steroid receptors compared with kinase clients [97]. Overall, celastrol maintains cellular homeostasis depending on HSF1-mediated protein homeostasis, up-regulating neuroprotective HSPs and down-regulating HSP90 expression.

**Celastrol directly binds to HMGB1 and inactivates it**

HMGB1 is a ubiquitous nuclear protein and a key molecular target bound up with many distinct human diseases. Human HMGB1 consists of 215 amino acid residues and includes two homologous DNA-binding domains named HMGB1 A-box and B-box, and a negatively charged C-terminal acidic tail [98]. Three cysteines (Cys23 and 45 in the A box, and Cys106 in the B box) mainly determine the redox status of HMGB1. Only disulfide isoform HMGB1 with Cys23 and Cys45 form an intramolecular disulfide bond and Cys106 in reduced state possesses pro-inflammatory activity by binding to receptor TLR4 [98]. Extracellular HMGB1 secreted by passive or active release is an important mediator and a biomarker of multiple diseases. In various preclinical inflammatory related disease models, HMGB1 antagonists such as anti-HMGB1 mAb, metformin and glycyrrhetinic acid (GA), have been verified effective by decreasing HMGB1 expression, release and activity [99, 100]. Previous studies have shown that celastrol ameliorated inflammatory pain and played neuroprotective effect by suppressing the activated HMGB1/NF-κB signaling pathway, and relieved rats myocardial I/R injury by inhibiting HMGB1 expression [69, 101, 102]. In our recent study regarding the effects of
Celastrol on cerebral I/R, we discovered that celastrol directly bound to HMGB1 and did not affect the expression, secretion and redox states of HMGB1. Celastrol inhibited the proinflammatory activity of disulfide isoform HMGB1 and HMGB1 B box by binding to it and preventing the binding of HMGB1 to its inflammatory receptors TLR4 and RAGE [27]. Our results suggested that celastrol inactivated HMGB1 to exhibit anti-inflammatory effect in ischemia stroke or other diseases. The deficiency is that the specific binding sites of celastrol to HMGB1 protein is uncertain in our research, and leaves something to be desired.

Celastrol is a ligand of Nur77 and covalently binds to Nur77

Nur77 (also known as TR3, NGFI-B and NR4A1), an orphan member of the nuclear receptor super family, acts as a promising target for anti-inflammatory therapy in metabolic and inflammatory diseases. Upregulation of Nur77 possesses neuroprotective effect and suppresses the pro-inflammatory genes expression through negatively regulating microglia activation-mediated dopaminergic neurotoxicity [103]. In astrocytes, increasing Nur77 expression with NR4A receptor ligand prevented nuclear export of Nur77, suppressed the transcriptional activity of NF-κB and its regulated inflammatory and apoptotic genes [104]. Nur77 was a direct intracellular anti-inflammatory target of celastrol by clearing inflamed mitochondria. Celastrol inhibited acute liver inflammation and chronic inflammation in obese animals by binding to Nur77 and promoting Nur77 translocation from the nucleus to mitochondria and interact with tumor necrosis factor receptor-associated factor 2 (TRAF2) [105]. TRAF2-Nur77 interaction inhibited TNF-α-induced ubiquitination of TRAF2 and Lys63-linked Nur77 ubiquitination. Ubiquitinated Nur77 interacted with p62/SQSTM1 by inducing autophagy to eliminate damaged mitochondria and contribute to anti-inflammatory function of celastrol. In addition, celastrol-induced Nur77 interaction with TRAF2 decreased the effects of TNF-α induced IκBα degradation by suppression of IKKα/β phosphorylation to inhibit the IKK-NF-κB pathway. In conclusion, celastrol alleviated inflammation through promoting mitochondrial ubiquitination and autophagy by inducing Nur77 interaction with TRAF2 and inhibiting the classical IKK/NF-κB pathway [105]. Six cysteines exist in Nur77 ligand-binding domain (LBD): C465, C475, C505, C534, C551 and C566. Celastrol covalently bound to the C551 reactive cysteine of Nur77 protein via a Michael addition reaction and induced Nur77 ubiquitination. C-6, one of the three electrophilic carbons in the quinone methide motif of celastrol, involved in an adduct formation. The covalent bond was reversible and required specific noncovalent interactions with Nur77 to position celastrol next to the thiol group of C551 [106]. Further research indicated that celastrol induced ubiquitination of Nur77 in the C-terminal and formed Nur77/p62 condensates coordinated multivalent interaction to mediate celastrol-induced mitophagy [107]. These results remind us think highly that cleastrol may also interact with Nur77 to exhibit neuroprotective effect in neurodegenerative diseases by inhibiting the IKK-NF-κB pathway.

Celastrol is a CB2 agonist

Mounting evidence shows that cannabinoid receptors type 1 and 2 (CB1 and CB2) possess different physiological properties. CB1 agonists possess neuroprotective properties with psychoactive side effects at effective doses, and CB2 agonists mainly mediate anti-inflammatory, suppression of microglia activation, neuroprotective, and immunomodulatory actions in animal models of neurodegenerative diseases [108]. Based on split luciferase complementation assay (SLCA) screening method, celastrol was confirmed as a new direct and selective CB2 agonist. Celastrol triggered several CB2-mediated downstream signaling pathways, such as inhibiting cAMP accumulation, calcium mobilization, inducing CB2 receptor desensitization, CB2 medicated β-arrestin 2 trafficking and CB2-dependent ERK activation. By upregulating CB2 expression, celastrol reduced inflammatory responses, alleviated renal fibrosis, inflammatory and neuropathic pain and prevented the development of systemic sclerosis [109-111]. The selective CB2 activation effect of celastrol may lay the foundation for other neurodegenerative diseases [112].

Celastrol inhibits STAT3 expression

By directly binding and inhibiting signal transducer and activator of transcription-3 (STAT3) tyrosine phosphorylation and nuclear translocation, celastrol protected against Ang II-induced cardiac dysfunction. Celastrol might bind to both SH2 (Gln-635/Val-637) domain and coiled-coil domain (CCD, Leu-207) of STAT3 to reduce its nuclear translocation and tyrosine phosphorylation [113]. In response to cytokines, hormones or growth factors, the canonical Janus kinases (JAK)-STAT3 pathway is activated through STAT3 phosphorylation, dimerization and accumulation in the nucleus. JAK-STAT3 pathway is emerging as a canonical inducer of astrocyte reactivity. STAT3 induces the astrogliosis reactivation, which plays key roles in modulating the adaptive responses in neurons and is a uniform response mechanism of the brain to acute or chronic neurological diseases [114]. Deleting STAT3 or
chronic treatment with a systemic STAT3 inhibitor normalized cerebral network activity, attenuated neuroinflammation and ameliorated cognitive decline of AD model mice [115]. Therefore, celastrol may play a neuroprotective role partly by inhibiting STAT3 activation in various neurodegenerative diseases, and relevant research is scarce.

**Celastrol directly binds and down-regulates hnRNPA1 expression**

Heterogeneous nuclear ribonucleoproteins (hnRNPs) are RNA-binding proteins that play complex biological processes. HnRNPs include 20 members in humans, and hnRNPA1 is the most abundant member of this family that regulates gene expression and RNA metabolism. Continuous evidence shows that hnRNPA1 plays an important role in the pathogenesis of neurodegenerative diseases, including familial ALS, MS, AD and stroke [116, 117]. By directly binding to the C terminus of IκBα, hnRNPA1 mediated the degradation of IκBα to influence the NF-κB activity and transcription of TNF-α [118, 119]. Our recent research also showed that celastrol accelerated the degradation of hnRNPA1 by directly binding with it, and modulated hnRNPA1-IκBα-NF-κB-TNF-α pathway to play a role in obesity-depression comorbidity [120]. Accordingly, it is speculated that celastrol may carry therapeutic potential for multiple neurodegenerative diseases by binding to hnRNPA1.

**By-effects caused by celastrol**

Due to the low water solubility, oral bioavailability, narrow dosage-window, short plasma half-life and side effects, clinical usage of celastrol is scarce at present. The major side effects of celastrol include infertility toxicity, cardiotoxicity, hepatotoxicity, hematopoietic system toxicity and so on [121]. The main toxicities of celastrol are presented in Figure 3. Next, we will introduce the studies in detail regarding the main side effects of celastrol.

![Figure 3. The main side effects of celastrol include microglia cytotoxicity, cardiotoxicity, hepatotoxicity, embryonal toxicity, infertility toxicity, hematopoietic system toxicity and potential risk of celastrol-drug interaction.](image-url)
**Microglia cytotoxicity**

In the low concentration, celastrol reduced the inflammatory response of microglia. However, celastrol induced cytotoxicity in microglia at high concentrations (100-1000 nM), evidenced by lactate dehydrogenase (LDH) assay, reduced cells viability, and most of trypan blue-positive cells showed cytoplasm shrinkage [12]. As an HSP70 agonist, celastrol reduced postkindling seizure thresholds. Meanwhile, celastrol might also exert pro-inflammatory detrimental effects through enhancing microglia activation via HSP70 signaling [122].

**Cardiotoxicity**

Celastrol showed cardiotoxic to zebrafish embryo with heart linearization, heart membrane hemorrhage, hemocytes accumulation in cardiac region and decreased heart rate [123]. Based on non-targeted metabolomics analysis, network toxicology study and biological approaches, male Wistar rats intraperitoneal injected with celastrol for successive 7 d (2 mg/kg/d, 1 mg/kg/d, 0.5 mg/kg/d) showed obvious heart damage, evidenced by significantly increased endogenous free fatty acid palmitic acid in plasma resulting in disrupted oxidative defense system. Excessive produced ROS further induced apoptosis by activating TNF signaling pathway and its downstream Caspase cascade [124]. Considering the druggability of celastrol as an anti-obesity medication, the security needs to be considered in the regulation of energy homeostasis. In an anti-obesity research, celastrol showed cardiovascular side effects with profound sympathoexcitatory effect, up regulating pro-inflammatory cytokines, potently reduced locomotor activity and potential muscle wasting [125]. Chronic exposure to celastrol potently inhibited both cardiac Kir2.1 and hERG potassium channels expression and caused QT prolongation to induce cardiotoxicity. Ascribe to the cardiotoxicity, celastrol acute blocked ion conduction, altered the rate of ion channel transport and reduced channel density on the cells surface [126].

**Hepatotoxicity**

The cytochrome P450 (CYP) is an enzyme family of membrane-bound hemoproteins that takes part in the detoxification of xenobiotics, cellular metabolism and homeostasis. CYP enzymes inhibition lays the foundation for inducing drug-drug interactions. Celastrol concentration-dependently inhibited different isoforms of CYP450 in reconstructed human liver microsomes and might cause the herb–drug interactions [127]. In primary rat hepatocytes, as an inhibitor of CYP450 metabolic enzymes, celastrol treatment (3, 10 and 30 μM) induced obvious hepatotoxicity with increased AST, LDH, and ROS productions and lowered \( \Delta \psi_m \) (low \( \Delta \psi_m \) is a sign of early apoptosis). The celastrol hepatotoxicity was enhanced with 1-aminobenzotriazole (the broad-spectrum inhibitor of CYP450s) and decreased with phenobarbital (a CYP450s enzyme inducer) [128].

**Embryonal toxicity**

Celastrol displayed toxicity to the normal development of zebrafish embryos in μM concentrations, confirmed by lower hatching rates, no blood flow in trunk vessels, serious edema in pericardial sac, tail malformation and lethal effect. No blood flow may also relate with the cardiotoxicity and antiangiogenic effects of celastrol [129]. However, whether celastrol exerts embryonal toxicity in rodents is unclear at present.

**Infertility toxicity**

Celastrol dose-dependently inhibited guinea pig spermatozoal functions of forward motility, capacitation, the acrosome reaction, and sperm penetration assay. The acrosome reaction inhibitory effect was partly reversible when the exposure of spermatozoa to celastrol was less than 3 h [130]. Furthermore, in mouse spermatogenic cells and the progesterone-initiated sperm acrosome reaction, celastrol significantly decreased the Ca\(^{2+}\) current time-dependently and irreversibly to play antifertility effect [131].

**Hematopoietic system toxicity**

For clarify the hematopoietic system effects of celastrol, mice were treated with celastrol daily intraperitoneal injection over the course of 4 days, and the 5 mg/kg/day celastrol treated mice showed signs of toxicity with hunched posture, ruffled fur and higher total white blood cells. Celastrol treatment showed hematotoxicity with specific impairment of the development of B cells and erythrocytes in peripheral blood (PB), bone marrow (BM), spleen and peritoneal cavity (PerC). In BM, the number of common lymphoid progenitors (CLP), common myeloid progenitors (CMP) and megakaryocyte-erythrocyte progenitors (MEPs) were also decreased, and the number of Granulocyte-Monocyte Progenitors (GMPs) increased. Therefore, celastrol may be a potential priming of CMPs to GMPs. Besides the hematotoxicity, based on the above results, proper dose of celastrol might be used to modulate the hematopoietic cells subset [132].

**Celastrol-drug interactions**
UDP-Glucuronosyltransferases (UGTs), which share many similarities with CYP450, are glycoproteins localized in the endoplasmic reticulum (ER) and function as important phase II metabolic enzymes to detoxicate different endogenous and exogenous compounds. Inhibiting the activity of compounds to UGTs may affect clinical drug-drug or herb-drug interactions [133]. Apart from inhibiting CYP450 to give rise to the herb-drug interactions, celastrol potently inhibited the UGT1A6 and 2B7-mediated 4-MU glucuronidation reaction, prevented the UGT1A8 activity competitively and decreased the activity of UGT1A10 noncompetitively. Therefore, the risk possibility of celastrol-drug interactions or celastrol-containing herbs-drug interactions may also exist in this form [134, 135].

Figure 4. The small molecule compound probes available at present to research for celastrol targets, and specific flow chart of celastrol related quantitative chemical proteomics. (A) The specific flow chart of quantitative chemical proteomics. (B) Small molecule compound probes available at present to research for celastrol targets and verified targets in different kinds of cells.

Apart from the above findings, the dosage and/or treatment duration or certain experiment conditions may play a role for by-effects of celastrol. For example, celastrol displayed NADPH oxidase (NOX) enzymes inhibitory activity to exert antioxidant capacity, and treatment with celastrol led to an increased rate of H2O2 production and induced cells death at higher concentrations (≥ 50 μM) [136]. Though as a potent proteasome inhibitor to exert anticancer effect, celastrol did not show any neuroprotective effect under conditions of ubiquitin-proteasome system (UPS) inhibition in PD model. The toxic effects of celastrol in this PD model might result from its proteasome inhibiting effects, the cells type and culture conditions [137]. Based upon thiol related HSP90 inhibition effect, celastrol induced cells cycle arrest at G0/G1 phase in U937 cells. The target protein spectrum of celastrol became broader along with increase of dose. Similarly, side effects were also dose-dependent. The direct binding reactions and reversing effects of celastrol and thiol-containing agents may help mitigating side effects of celastrol. Thiol-containing agents decreased the targeting effect of celastrol on cellular thiols by forming competition with the cellular thiols [138]. In addition, protein denaturing or adding irreversible cysteine alkylation reagents also could partially disrupt the interaction of celastrol and protein thiols [139]. Overall, though celastrol exerts toxicity in multiple in vitro and in vivo models, future studies to further investigate the specific concentration range, time frame and underlying mechanism for the toxicity effects of celastrol are interesting topics. The studies on improving oral bioavailability, toxicity reduction and maximize efficacy of celastrol will further step into a new phase with the progress of nanotechnology, quantitative chemical proteomics, single cell sequencing and in-depth research of mechanisms. For example, nanotechnology-based numerous celastrol formulations have been widely investigated and showed great success to reduce systemic
toxicity and enhance the bioavailability of celastrol [140, 141].

Current available drug-probes for celastrol quantitative chemical proteomics research

Quantitative chemical proteomics has been applied to multifarious traditional medicine and small molecular compounds to identify small molecule-protein interactions, such as artemisinin, andrographolide, curcumin, aspirin, etc [142]. We summarize small molecule compound probes available at present to research for celastrol targets, and specific flow chart of celastrol related quantitative chemical proteomics is shown in Figure 4.

By utilizing an iodoacetamide-derived cysteine-reactive probe (iodoacetamide-alkyne, 1A-yn), the authors identified over 60 binding proteins of celastrol in the human cervical cancer HeLa cells proteome via a competitive chemo-proteomics approach. However, only three reported targets (HSP90 co-chaperone Cdc37, Annexin A2, and elongation factor 1-alpha 1 (eEF1A)) were in concert with previously reported celastrol binding proteins, which may be due to the relatively low alklyation efficiency of celastrol to the rest proteins (HSP90β, Prostaglandin E synthase 3 (p23), NF-kB, Proteasomes, Peroxiredoxin-1, and β-Tubulin chain) [137]. Based on a biotin-labeled celastrol (Bio-celastrol), more than 100 proteins of celastrol potential targets were identified. Top interacting proteins binding to celastrol were peroxiredoxin proteins, VHS (Vps27-Hrs-STAM)-domain containing proteins, and STAT proteins [113]. Based on biotinylated celastrol-probes and performing affinity pull-down experiments in extracts of human pancreatic carcinoma (PANC-1) cells, the potential cellular targets of celastrol were identified (Annexin II, eEF1A, and β-tubulin). HSP90 appeared to be an indirect target of celastrol by invoking a redox imbalance [143]. Significantly, our research group developed an activity-based celastrol-probe (cel-p). Based upon this alkyne linked cel-p, we have studied the direct protein binding targets of celastrol in ischemia stroke and obesity-depression comorbidity. In BV2 cells and primary rat cortical neurons, we identified 341 and 120 proteins respectively, and we chose hnRNPA1 and HMGB1 proteins as the directly binding targets for verifying [27, 120]. Furthermore, our team has also studied the treatment of liver fibrosis, sepsis and other CNS diseases with celastrol and cel-p (unpublished data).

Conclusion

With the aging of population and changes in lifestyles, the number of patients suffering from neurodegenerative diseases is increasing, which represents an enormous burden in terms of both health and economic costs. A growing body of evidence suggests that the anti-oxidative stress and anti-inflammatory responses of celastrol significantly contribute to the pathology of these debilitating diseases. At present, the pharmacological and toxicological studies of celastrol are mainly concentrated in the preclinical stage, which possible due to used high concentrations and side effects. The above studies provide promising preclinical evidence of celastrol in the treatment of neurodegenerative diseases, which is of great value for further clinical study and evaluation. However, many therapies or small molecular compounds that prevent oxidative damage or inhibit neuroinflammation have exhibited good effect in preclinical studies, when converting from basic to clinical research there is little success. Deciphering the molecular codes of celastrol preserves promising prospects for medical science and clinical application to improve therapeutic strategies decrease side effects and extend a new departure. Furthermore, studies have carried out to confirm that celastrol has different effects at different doses, and how celastrol affects tissues at different doses still needs to be further clarified.

Acknowledgements

We gratefully acknowledge financial support from the National Key Research and Development Program of China (2020YFA0908000); the Innovation Team and Talents Cultivation Program of National Administration of Traditional Chinese Medicine (No: ZYYCXTD-C-202002); the Shenzhen Science and Technology Innovation Commission (JCYJ20210324115800001, JCYJ20210324114014039); the Sanming Project of Medicine in Shenzhen (Grant No. SZSM201612034); the National Natural Science Foundation of China (82074098 and 81841001); the National Key R&D Program of China (2020YFE020510); the CACMS Innovation Fund (2021A05101); the Fundamental Research Funds for the Central public welfare research institutes (ZZ15-QY-063, ZZ13-ZD-07, ZZ14-YQ-050, ZZ14-FL-010, ZZ14-ND-010 and ZZ15-ND-10).

Competing interests

The authors declare that there are no disputes of interest.

References

[1] Lipsky PE, Tao XL (1997). A potential new treatment for rheumatoid arthritis: thunder god vine. Semin
Arthritis Rheum, 26:713-723.

Kannaiyan R, Shanmugam MK, Sethi G (2011). Molecular targets of celastrol derived from Thunder of God Vine: potential role in the treatment of inflammatory disorders and cancer. Cancer Lett, 303:9-20.

Li J, Hao J (2019). Treatment of Neurodegenerative Diseases with Bioactive Components of Tripterygium wilfordii. Am J Chin Med, 47:769-785.

Ng SW, Chan Y, Chellappan DK, Madheswaran T, Zeeshan F, ChanYL, et al (2019). Molecular modulators of celastrol as the keystones for its diverse pharmacological activities. Biomed Pharmacother, 109:1785-1792.

Erkkinen MG, Kim MO, Geschwind MD (2018). Clinical Neurology and Epidemiology of the Major Neurodegenerative Diseases. Csh Perspect Biol, 10:1-44.

Xu L, He D, Bai Y (2016). Microglia-Mediated Inflammation and Neurodegenerative Disease. Mol Neurobiol, 53:6709-6715.

Thompson KS, Tsirka S (2017). The Diverse Roles of Microglia in the Neurodegenerative Aspects of Central Nervous System (CNS) Autoimmunity. Int J Mol Sci, 18:504.

Wang J, Xing H, Wan L, Jiang X, Wang C, Wu Y (2018). Treatment targets for M2 microglia polarization in ischemic stroke. Biomed Pharmacother, 105:518-525.

Tang Y, Le W (2016). Differential Roles of M1 and M2 Microglia in Neurodegenerative Diseases. Mol Neurobiol, 53:1181-1194.

Nakamichi K, Kitani H, Takayama-Ito M, Morimoto K, Kurane I, Saijo M (2010). Celastrol suppresses morphological and transcriptional responses in microglial cells upon stimulation with double-stranded RNA. Int J Neurosci, 120:252-257.

Jung HW, Chung YS, Kim YS, Park YK (2007). Celastrol inhibits production of nitric oxide and proinflammatory cytokines through MAPK signal transduction and NF-kappaB in LPS-stimulated BV-2 microglial cells. Exp Mol Med, 39:715-721.

Dai W, Wang X, Teng H, Li C, Wang B, Wang J (2019). Celastrol inhibits microglial pyroptosis and attenuates inflammatory reaction in acute spinal cord injury rats. Int Immunopharmacol, 66:215-223.

Jiang M, Liu X, Zhang D, Wang Y, Hu X, Xu F, et al (2018). Celastrol treatment protects against acute ischemic stroke-induced brain injury by promoting an IL-33/ST2 axis-mediated microglia/macrophage M2 polarization. J Neuroinflamm, 15:78.

Gorshkov K, Aguusanda F, Thorne N, Zheng W (2018). Astrocytes as targets for drug discovery. Drug Discov Today, 23:673-680.

Ben Haim L, Carrillo-de Sauvage MA, Ceyzériat K, Esclmont C (2015). Elusive roles for reactive astrocytes in neurodegenerative diseases. Front Cell Neurosci, 9:1-27.

Youn GS, Kwon DJ, Ju SM, Rhim H, Bae YS, Choi SY, et al (2014). Celastrol ameliorates HIV-1 Tat-induced inflammatory responses via NF-kappaB and AP-1 inhibition and heme oxygenase-1 induction in astrocytes. Toxicol Appl Pharmacol, 280:42-52.

An SY, Youn GS, Kim H, Choi SY, Park J (2017). Celastrol suppresses expression of adhesion molecules and chemokines by inhibiting JNK-STAT1/NF-kB activation in poly(I:C)-stimulated astrocytes. BMB Rep, 50:25-30.

Paris D, Ganey NJ, Laporte V, Patel NS, Beaulieu-Abdelahad D, Bachmeier C, et al (2010). Reduction of beta-amyloid pathology by celastrol in a transgenic mouse model of Alzheimer's disease. J Neuroinflamm, 7:17.

Clener C, Calingasan NY, Chen J, Beal MF (2005). Celastrol protects against MPTP- and 3-nitropropionic acid-induced neurotoxicity. J Neurochem, 94:995-1004.

Branca JJV, Morucci G, Pacini A (2018). Cadmium-induced neurotoxicity: still much ado. Neural Regen Res, 13:1879-1882.

Huat TJ, Camats-Perna J, Newcombe EA, Valmas N, Kitazawa M, Medeiros R (2019). Metal Toxicity Links to Alzheimer's Disease and Neuroinflammation. J Mol Biol, 431:1843-1868.

Chen S, Gu C, Xu C, Zhang J, Xu Y, Ren Q, et al (2014). Celastrol prevents cadmium-induced neuronal cell death via targeting JNK and PTEN-Akt/mTOR network. J Neurochem, 128:256-266.

Luo D, Guo Y, Cheng Y, Zhao J, Wang Y, Rong J (2017). Natural product celastrol suppressed macrophage M1 polarization against inflammation in diet-induced obese mice via regulating Nrf2/HO-1, MAP kinase and NF-kB pathways. Aging (Albany NY), 9:2069-2082.

Zhang R, Zhang N, Zhang H, Liu C, Dong X, Wang X, et al (2017). Celastrol prevents cadmium-induced neuronal cell death by blocking reactive oxygen species-mediated mammalian target of rapamycin pathway. Br J Pharmacol, 174:82-100.

Xu C, Wang X, Gu C, Zhang H, Zhang R, Dong X, et al (2017). Celastrol ameliorates Cd-induced neuronal apoptosis by targeting NOX2-derived ROS-dependent PP5-JNK signaling pathway. J Neurochem, 141:48-62.

Lin MW, Lin CC, Chen YH, Yang HB, Hung SY (2019). Celastrol Inhibits Dopaminergic Neuronal Death of Parkinson's Disease through Activating Mitophagy. Antioxidants (Basel), 9.

Liu DD, Luo P, Gu L, Zhang Q, Gao P, Zhu Y, et al (2021). Celastrol exerts a neuroprotective effect by directly binding to HMG1 protein in cerebral ischemia-reperfusion. J Neuroinflamm, 18:174.

Costea L, Mészáros Á, Bauer H, Bauer HC, Traweger S, Bräunlich J, et al (2019). The Blood–Brain Barrier and Its Intercellular Junctions in Age-Related Brain Disorders. Int J Mol Sci, 20.

Yang C, Hawkins KE, Doré S, Candelario-Jalil E (2019). Neuroinflammatory mechanisms of blood-brain barrier damage in ischemic stroke. Am J Physiol Cell Physiol, 316:C135-C153.

Luo D, Zhao J, Rong J (2016). Plant-derived triterpene...
celestral ameliorates oxygen glucose deprivation-induced disruption of endothelial barrier assembly via inducing tight junction proteins. Phytomedicine, 23:1621-1628.

[31] Xu H, Cai Y, Yu M, Sun J, Cai J, Li J, et al (2021). Celestral protects against early brain injury after subarachnoid hemorrhage in rats through alleviating blood-brain barrier disruption and blocking necroptosis. Aging (Albany NY), 13:16816-16833.

[32] Metselaar D, Meel M, Benedict B, Warannecki P, Koster J, Kaspers G, et al (2019). Celestral-induced degradation of FANCD2 sensitizes pediatric high-grade gliomas to the DNA-crosslinking agent carboplatin. EBioMedicine, 50:81-92.

[33] Paloczi J, Varga Z, Hasko G, Pacher P (2018). Neuroprotection in Oxidative Stress-Related Neurodegenerative Diseases: Role of Endocannabinoid System Modulation. Antioxid Redox Sign, 29:75-108.

[34] Serwach K, Gruszczynska-Biegala J (2019). STIM Proteins and Glutamate Receptors in Neurons: Role in Neuronal Physiology and Neurodegenerative Diseases. Int J Mol Sci, 20.

[35] Godini R, Fallahi H, Ebrahimie E (2019). A comparative system-level analysis of the neurodegenerative diseases. J Cell Physiol, 234.

[36] Amor S, Puentes F, Baker D, van der Valk P (2010). Inflammation in neurodegenerative diseases. Immunology, 129:154-169.

[37] Liao WT, Xiao XY, Zhu Y, Zhou SP (2018). The effect of celestral on learning and memory in diabetic rats after sevoflurane inhalation. Arch Med Sci, 14:370-380.

[38] Xiao Y, Wang X, Wang S, Li J, Xu X, Wang M, et al (2021). Celestral Ameliorates Learning and Memory Deficits in an Alzheimer's Disease Rat Model. Biomed Res Int., 2021:5574207.

[39] Cao F, Wang Y, Peng B, Zhang X, Zhang D, Xu L (2018). Effects of celestral on Tau hyperphosphorylation and expression of HSF-1 and HSP70 in SH-SY5Y neuroblastoma cells induced by amyloid-β peptides. Biotechnol Appl Biochem, 65:390-396.

[40] Wang X, Cattaneo F, Ryno L, Hullemen J, Reixach N, Buxbaum JN (2014). The systemic amyloid precursor transthyretin (TTR) behaves as a neuronal stress protein regulated by HSF1 in SH-SY5Y human neuroblastoma cells and APP23 Alzheimer's disease model mice. J Neurosci, 34:7253-7265.

[41] Choi SH, Leighton SN, Lee VM, Li T, Wong PC, Johnson JA, et al (2007). Accelerated Abeta deposition in APPsw+PS1deltaE9 mice with hemizygous deletions of TTR (transthyretin). J Neurosci, 27:7006-7010.

[42] Buxbaum JN, Ye Z, Reixach N, Friske L, Levy C, Das P, et al (2008). Transthyretin protects Alzheimer's mice from the behavioral and biochemical effects of Abeta toxicity. Proc Natl Acad Sci U S A, 105:2681-2686.

[43] Zhao Y, Zhao H, Lobo N, Guo X, Gentleman SM, Ma D (2014). Celestral enhances cell viability and inhibits amyloid-β production induced by lipopolysaccharide in vitro. J Alzheimers Dis, 41:835-844.

[44] Pang SY, Ho PW, Liu HF, Leung CT, Li L, Chang EES, et al (2019). The interplay of aging, genetics and environmental factors in the pathogenesis of Parkinson's disease. Transl Neurodegener, 8:23.

[45] Faust K, Gehrke S, Yang Y, Yang L, Beal MF, Lu B (2009). Neuroprotective effects of compounds with antioxidant and anti-inflammatory properties in a Drosophila model of Parkinson's disease. BMC Neurosci, 10:109.

[46] Zhang C, Zhao M, Wang B, Su Z, Guo B, Qin L, et al (2021). The Nrfl-2-NLRP3-caspase-1 axis mediates the neuroprotective effects of Celestral in Parkinson's disease. Redox Biol, 47:102134.

[47] Choi BS, Kim H, Lee HJ, Sapkota K, Park SE, Kim S, et al (2014). Celestral from 'Thunder God Vine' protects SH-SY5Y cells through the preservation of mitochondrial function and inhibition of p38 MAPK in a rotenone model of Parkinson's disease. Neurochem Res, 39:84-96.

[48] Moors TE, Hoozemans JJ, Ingrassia A, Beccari T, Parnetti L, Chartier-Harlin MC, et al (2017). Therapeutic potential of autophagy-enhancing agents in Parkinson's disease. Mol Neurodegener, 12:11.

[49] Chaudhuri A (2013). Multiple sclerosis is primarily a neurodegenerative disease. J Neural Transm (Vienna), 120:1463-1466.

[50] Vidal-Jordana A, Montalban X (2017). Multiple Sclerosis: Epidemiologic, Clinical, and Therapeutic Aspects. Neuroimaging Clin N Am, 27:195-204.

[51] Venkatesha SH, Moudgil KD (2019). Celestral Ameliorates Multiple Sclerosis and Optic Neuritis in an Experimental Autoimmune Encephalomyelitis Model. Front Pharmacol, 8:44.

[52] Yang H, Liu C, Jiang J, Wang Y, Zhang X (2017). Celestral Ameliorates Multiple Sclerosis and Optic Neuritis in an Experimental Autoimmune Eencephalomyelitis Model. Front Pharmacol, 8:44.

[53] Venkatesha SH, Moudgil KD (2019). Celestral suppresses experimental autoimmune encephalomyelitis via MAPK/SIK1-regulated mediators of autoimmune pathology. Inflamm Res, 68:285-296.

[54] Abdin AA, Hasby EA (2014). Modulatory effect of celestral on Th1/Th2 cytokine expression, TLR2 and CD3+ T-lymphocyte expression in a relapsing-remitting model of multiple sclerosis in rats. Eur J Pharmacol, 742:102-112.

[55] van den Bos MAJ, Geevasinga N, Higashihara M, Menon P, Vucic S (2019). Pathophysiology and Diagnosis of ALS: Insights from Advances in Neuropsychological Techniques. Int J Mol Sci, 20.

[56] Kiae M, Kipiani K, Petri S, Chen J, Calingasan NY, Beal MF (2005). Celestral blocks neuronal cell death and extends life in transgenic mouse model of amyotrophic lateral sclerosis. Neurodegener Dis, 2:246-254.

[57] Kalmar B, Greensmith L (2009). Activation of the heat shock response in a primary cellular model of neuroprotection.
motoneuron neurodegeneration—evidence for neuroprotective and neurotoxic effects. Cell Mol Biol Lett, 14:319-335.

[58] Westerheide SD, Bosman JD, Mbadugha BN, Kawahara TL, Matsumoto G, Kim S, et al (2004). Celastrols as inducers of the heat shock response and cytoprotection. J Biol Chem, 279:56053-56060.

[59] Nopoulos P (2016). Huntington disease: a single-gene degenerative disorder of the striatum. Dialogues Clin Neuro, 18:91-98.

[60] Wang J, Gines S, MacDonald ME, Gusella JF (2005). Reversal of a full-length mutant huntingtin neuronal cell phenotype by chemical inhibitors of polyglutamine-mediated aggregation. BMC Neurosci, 6:1.

[61] Zhang YQ, Sarge KD (2007). Celastrol inhibits polyglutamine aggregation and toxicity through induction of the heat shock response. J Mol Med (Berl), 85:1421-1428.

[62] Klockgether T, Mariotti C, Paulson HL (2019). Spinecerebellar ataxia. Nat Rev Dis Primers, 5:24.

[63] Nakazono A, Adachi N, Takahashi H, Seki T, Hamada D, Ueyama T, et al (2018). Pharmacological induction of heat shock proteins ameliorates toxicity of mutant PKCy in spinecerebellar ataxia type 14. J Biol Chem, 293:14758-14774.

[64] Ye F, Garton H, Hua Y, Keep R, Xi G (2021). The Role of Thrombin in Brain Injury After Hemorrhagic and Ischemic Stroke. Transl Stroke Res, 12:496-511.

[65] Durukan A, Tatlisumak T (2007). Acute ischemic stroke: overview of major experimental rodent models, pathophysiology, and therapy of focal cerebral ischemia. Pharmacol Biochem Be, 87:179-197.

[66] Lu C, Zhang X, Zhang D, Pei E, Xu J, Tang T, et al (2015). Short time triperine treatment enhances endothelial progenitor cell function via heat shock protein 32. J Cell Physiol, 230:1139-1147.

[67] Li Y, He D, Zhang X, Liu Z, Zhang X, Dong L, et al (2012). Protective effect of celastrol in rat cerebral ischemia model: down-regulating p-JNK, p-e-Jun and NF-xB. Brain Res, 1464:8-13.

[68] Yang Y, Liu H, Zhang H, Ye Q, Wang J, Yang B, et al (2017). ST2/IL-33-Dependent Microglial Response Limits Acute Ischemic Brain Injury. J Neurosci, 37:4692-4704.

[69] Zhang B, Zhong Q, Chen X, Wu X, Sha R, Song G, et al (2020). Neuroprotective Effects of Celastrol on Transient Global Cerebral Ischemia Rats via Regulating HMGB1/NF-xB Signaling Pathway. Front Neurosci-Switz, 14:847.

[70] Liu M, Chen M, Luo Y, Wang H, Huang H, Peng Z, et al (2021). Lipidomic Profiling of Ipsilateral Brain and Plasma after Celastrol Post-Treatment in Transient Middle Cerebral Artery Occlusion Mice Model. Molecules (Basel), 26.

[71] Wang C, Wan H, Li M, Zhang C (2021). Celastrol attenuates ischemia/reperfusion-mediated memory dysfunction by downregulating AK005401/MAPK3K12. Phytomedicine, 82:153441.

[72] Cruz-Haces M, Tang J, Acosta G, Fernandez J, Shi R (2017). Pathological correlations between traumatic brain injury and chronic neurodegenerative diseases. Transl Neurodegener, 6:20.
Ma X, Xu L, Alberobello AT, Gavrilova O, Bagattin A, Skarulis M, et al (2015). Celastrol Protects against Obesity and Metabolic Dysfunction through Activation of a HSF1-PGC1α Transcriptional Axis. Cell Metab, 22:695-708.

Austin S, St-Pierre J (2012). PGC1α and mitochondrial metabolism—emerging concepts and relevance in ageing and neurodegenerative disorders. J Cell Sci, 125:4963-4971.

Kampfinga HH, Bergink S (2016). Heat shock proteins as potential targets for protective strategies in neurodegeneration. Lancet Neurol, 15:748-759.

Chow AM, Brown IR (2007). Induction of heat shock proteins in differentiated human and rodent neurons by celastrol. Cell Stress Chaperon, 12:237-244.

Chow AM, Tang DW, Hanif A, Brown IR (2013). Induction of heat shock proteins in cerebral cortical cultures by celastrol. Cell Stress Chaperon, 18:155-160.

Chow AM, Tang DW, Hanif A, Brown IR (2014). Localization of heat shock proteins in cerebral cortical cultures following induction by celastrol. Cell Stress Chaperon, 19:845-851.

Pratt WB, Gestwicki JE, Osawa Y, Lieberman AP (2015). Targeting Hsp90/Hsp70-based protein quality control for treatment of adult onset neurodegenerative diseases. Annu Rev Pharmacol Toxicol, 55:353-371.

Sreeramulu S, Gande SL, Göbel M, Schwalbe H (2009). Molecular mechanism of inhibition of the human protein complex Hsp90-Cdc37, a kinome chaperone-cochaperone, by triterpene celastrol. Angew Chem Int Ed Engl, 48:5853-5855.

Zhang T, Hamza A, Cao X, Wang B, Yu S, Zhan CG, et al (2008). A novel Hsp90 inhibitor to disrupt Hsp90/Cdc37 complex against pancreatic cancer cells. Mol Cancer Ther, 7:162-170.

Hieronymus H, Lamb J, Ross KN, Peng XP, Clement C, Rodina A, et al (2006). Gene expression signature-based chemical genomic prediction identifies a novel class of HSP90 pathway modulators. Cancer Cell, 10:321-330.

Chadli A, Felts SJ, Wang Q, Sullivan WP, Botuyan MV, Fauq A, et al (2010). Celastrol inhibits Hsp90 chaperoning of steroid receptors by inducing fibrillation of the Co-chaperone p23. J Biol Chem, 285:4224-4231.

Kwak M, Kim H, Lee B, Kim Y, Son M, Shin J (2020). Immunological Significance of HMBG1 Post-Translational Modification and Redox Biology. Front Immunol, 11:1189.

Yang H, Wang H, Andersson U (2020). Targeting Inflammation Driven by HMBG1. Front Immunol, 11:484.

Kang R, Chen R, Zhang Q, Hou W, Wu S, Cao L, et al (2014). HMBG1 in health and disease. Mol Aspects Med, 40:1-116.

Zhang X, Zhao W, Liu X, Huang Z, Shan R, Huang C (2019). Celastrol ameliorates inflammatory pain and modulates HMBG1/NF-kB signaling pathway in dorsal root ganglion. Neurosci Lett, 692:83-89.

Tong S, Zhang L, Joseph J, Jiang X (2018). Celastrol pretreatment attenuates rat myocardial ischemia/reperfusion injury by inhibiting high mobility group box 1 protein expression via the PI3K/Akt pathway. Biochem Bioph Res Co, 497:843-849.

Liu TY, Yang XY, Zheng LT, Wang GH, Zhen XC (2017). Activation of Nur77 in microglia attenuates proinflammatory mediators production and protects dopaminergic neurons from inflammation-induced cell death. J Neurochem, 140:589-604.

Popichak KA, Hammond SL, Moreno JA, Afzali MF, Backos DS, Slayden RD, et al (2018). Compensatory Expression of Nur77 and Nur1 Regulates NF-kB-Dependent Inflammatory Signaling in Astrocytes. Mol Pharmacol, 94:1174-1186.

Hu M, Luo Q, Ali tongbieke G, Chong S, Xu C, Xie L, et al (2017). Celastrol-Induced Nur77 Interaction with TRAF2 Alleviates Inflammation by Promoting Mitochondrial Ubiquitination and Autophagy. Mol Cell, 66:141-153:e146.

Zhang D, Chen Z, Hu C, Yan S, Li Z, Lian B, et al (2018). Celastrol binds to its target protein via specific noncovalent interactions and reversible covalent bonds. Chem Commun (Camb), 54:12871-12874.

Peng S, Chen X, Chen S, Zhang J, Wang C, Liu W, et al (2021). Phase separation of Nur77 mediates celastrol-induced mitophagy by promoting the liquidity of p62/SQSTM1 condensates. Nat Commun, 12:5989.

Rom S, Persidsky Y (2013). Cannabinoid receptor 2: potential role in immunomodulation and neuroinflammation. J Neuroimmune Pharmacol, 8:608-620.

Jiang X, Chen S, Zhang Q, Yi C, He J, Ye X, et al (2020). Celastrol is a novel selective agonist of cannabinoid receptor 2 with anti-inflammatory and anti-feribotic activity in a mouse model of systemic sclerosis. Phytomedicine, 67:153160.

Michl J, Ingrouille MJ, Simmonds MS, Heinrich M (2014). Naturally occurring aristolochic acid analogues and their toxicities. Nat Prod Rep, 31:676-693.

Tang M, Cao X, Zhang K, Li Y, Zheng QY, Li GQ, et al (2018). Celastrol alleviates renal fibrosis by upregulating cannabinoid receptor 2 expression. Cell Death Dis, 9:601.

Bisogno T, Oddi A, Piccoli F, Fazio D, Maccarrone M (2016). Type-2 cannabinoid receptors in neurodegeneration. Pharmacol Res, 111:721-730.

Ye S, Luo W, Khan ZA, Wu G, Xuan L, Shan P, et al (2020). Celastrol Attenuates Angiotensin II Induced Cardiac Remodeling by Targeting STAT3. Circ Res, 126:1007-1023.

Ceyzériat K, Abjean L, Carrillo de Sauvage MA, Ben Haim L, Escartin C (2016). The complex STATes of astrocyte reactivity: How are they controlled by the JAK-STAT3 pathway? Neuroscience, 330:205-218.

Reichenbach N, Delekat A, Plescher M, Schmitt F, Krauss S, Blank N, et al (2019). Inhibition of Stat3-mediated astrogliosis ameliorates pathology in an...
Alzheimer's disease model. EMBO Mol Med, 11.

Beijer D, Kim H, Guo L, O’Donovan K, Mademan I, Deconinck T, et al (2021). Characterization of HNRNPA1 mutations defines diversity in pathogenic mechanisms and clinical presentation. JCI insight, 6.

Kahl A, Blanco I, Jackman K, Baskar J, Milaganur Mohan H, Rodney-Sandy R, et al (2018). Cerebral ischemia induces the aggregation of proteins linked to neurodegenerative diseases. Sci Rep, 8:2701.

Sahu I, Sangith N, Ramteke M, Gadre R, Venkatraman P (2014). A novel role for the proteasomal chaperone PSMD9 and hNRNPA1 in enhancing IxkB degradation and NF-xB activation - functional relevance of predicted PDZ domain-motif interaction. FEBS J, 281:2688-2709.

Hay DC, Kemp GD, Dargemont C, Hay RT (2001). Interaction between hNRNPA1 and IxkB Is Required for Maximal Activation of NF-xB-Dependent Transcription. Mol Cell Biol, 21:3482-3490.

Zhu C, Yang J, Zhu Y, Li J, Chi H, Tian C, et al (2021). Celastrol alleviates comorbid obesity and depression by directly binding amygdala HnRNPA1 in a mouse model. Clin Transl Med, 11:e359.

Hou W, Liu B, Xu H (2020). Celastrol: Progresses in structure-modifications, structure-activity relationships, pharmacology and toxicology. Eur J Med Chem, 189:112081.

Von Rüden EL, Wolf F, Gualtieri F, Keck M, Hunt CR, Pandita TK, et al (2019). Genetic and Pharmacological Targeting of Heat Shock Protein 70 in the Mouse Amygdala-Kindling Model. ACS Chem Neurosci, 10:1434-1444.

Wang SF, Liu KC, Wang XM, He QX, Hou HR (2009). Preliminary study on cardiotoxicity of celastrol to zebrafish embryo. Chinese Pharmacol Bull, 25:634-635+636.

Dreschers S, Ohi K, Lehrke M, Möllmann J, Denecke B, Costa I, et al (2019). Impaired cellular energy metabolism in cord blood macrophages contributes to abortive response toward inflammatory threats. Nat Commun, 10:1685.

Saito K, Davis KC, Morgan DA, Toth BA, Jiang J, Singh U, et al (2019). Celastrol Reduces Obesity in MC4R Deficiency and Stimulates Sympathetic Nerve Activity Affecting Metabolic and Cardiovascular Functions. Diabetes, 68:1210-1220.

Sun H, Liu X, Xiong Q, Shikano S, Li M (2006). Chronic inhibition of cardiac Kir2.1 and HERG potassium channels by celastrol with dual effects on both ion conductivity and protein trafficking. J Biol Chem, 281:5877-5884.

Jin C, He X, Zhang F, He L, Chen J, Wang L, et al (2015). Inhibitory mechanisms of celastrol on human liver cytochrome P450 1A2, 2C19, 2D6, 2E1 and 3A4. Xenobiotica, 45:571-577.

Qiu D, Chu X, Hua L, Yang Y, Li K, Han Y, et al (2019). Gprl474-deficient regulatory T cells decrease cytokine storm in septic mice. Cell Death Dis, 10:233.

Wang S, Liu K, Wang X, He Q, Chen X (2011). Toxic effects of celastrol on embryonic development of zebrafish (Danio rerio). Drug Chem Toxicol, 34:61-65.

Yuan YY, Gu ZP, Shi QX, Qin GW, Xu RS, Cao L (1995). [In vitro inhibition of celastrol on spermatozoa fertilization ability of guinea pig]. Yao Xue Xue Bao, 30:331-335.

Bai JP, Shi YL, Fang X, Shi QX (2003). Effects of demethylzeylasteral and celastrol on spermatico-genital cell Ca2+ channels and progesterone-induced sperm acrosome reaction. Eur J Pharmacol, 464:9-15.

Kusy S, Ghosn EE, Herzenberg LA, Contag CH (2012). Development of B cells and erythrocytes is specifically impaired by the drug celastrol in mice. PLoS One, 7:e35733.

Radominska-Pandya A, Czernik PJ, Little JM, Battaglia E, Mackenzie PI (1999). Structural and functional studies of UDP-glucuronosyltransferases. Drug Metab Rev, 31:817-899.

Zhang YS, Tu YY, Gao XC, Yuan J, Li G, Wang L, et al (2012). Strong inhibition of celastrol towards UDP-glucuronosyl transferase (UGT) 1A6 and 2B7 indicating potential risk of UGT-based herb-drug interaction. Molecules (Basel), 17:6832-6839.

Qiu X, Liu X, Deng Y (2012). Prediction of Drug-Drug Interaction Due to the Inhibition of Specific Intestinal Drug-Metabolizing Enzymes by Celastrol. Lat Am J Pharm, 31:1501-1504.

Peng B, Xu L, Cao F, Wei T, Yang C, Uzam G, et al (2010). HSP90 inhibitor, celastrol, arrests human monocytic leukemia cell U937 at G0/G1 in thiol-containing agents reversible way. Mol Cancer, 9:79.

Zhou Y, Li W, Wang M, Zhang X, Zhang H, Tong X, et al (2016). Competitive profiling of celastrol targets in human cervical cancer HeLa cells via quantitative chemical proteomics. Mol Biosyst, 13:83-91.

Whitehouse S, Chen PL, Greenshields AL, Nightingale M, Hoskin DW, Bedard K (2016). Resveratrol, piperine and apigenin differ in their NADPH-oxidase inhibitory and reactive oxygen species-scavenging properties. Phytomedicine, 23:1494-1503.

Konieczny J, Jantas D, Lenda T, Domín H, Czarnecka A, Kuter K, et al (2014). Lack of neuroprotective effect of celastrol under conditions of proteasome inhibition by lactacystin in in vitro and in vivo studies: implications for Parkinson's disease. Neurotox Res, 26:255-273.

Fang G, Tang B (2020). Current advances in the nanodelivery of celastrol for treating inflammation-associated diseases. J Mater Chem B, 8:10954-10965.

Wagh P, Desai P, Prabhu S, Wang J (2021). Nanotechnology-Based Celastrol Formulations and Their Therapeutic Applications. Front Pharmacol, 12:673209.

Wang J, Gao L, Lee YM, Kalesh KA, Ong YS, Lim J, et al (2016). Target identification of natural and traditional medicines with quantitative chemical proteomics approaches. Pharmacol Ther, 162:10-22.

Klaic L, Morimoto RI, Silverman RB (2012). Celastrol analogues as inducers of the heat shock response. Design and synthesis of affinity probes for
the identification of protein targets. ACS Chem Biol, 7:928-937.